Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPELIAS, Eliana VaninaCASTRO, Nadia Pereira dePINEDA, Paulo Henrique BaldanABUAZAR, Carolina SensOSORIO, Cynthia Aparecida Bueno de ToledoPINILLA, Mabel GigliolaSILVA, Sabrina Daniela daCAMARGO, Anamaria AranhaSILVA JR., Wilson AraujoFERREIRA, Elisa Napolitano eBRENTANI, Helena PaulaCARRARO, Dirce Maria2017-02-162017-02-162016ONCOTARGET, v.7, n.46, p.75672-75684, 20161949-2553https://observatorio.fm.usp.br/handle/OPI/18002Breast cancer biomarkers that can precisely predict the risk of progression of non-invasive ductal carcinoma in situ (DCIS) lesions to invasive disease are lacking. The identification of molecular alterations that occur during the invasion process is crucial for the discovery of drivers of transition to invasive disease and, consequently, biomarkers with clinical utility. In this study, we explored differences in gene expression in mammary epithelial cells before and after the morphological manifestation of invasion, i.e., early and late stages, respectively. In the early stage, epithelial cells were captured from both pre-invasive lesions with distinct malignant potential [pure DCIS as well as the in situ component that co-exists with invasive breast carcinoma lesions (DCIS-IBC)]; in the late stage, epithelial cells were captured from the two distinct morphological components of the same sample (in situ and invasive components). Candidate genes were identified using cDNA microarray and rapid subtractive hybridization (RaSH) cDNA libraries and validated by RT-qPCR assay using new samples from each group. These analyses revealed 26 genes, including 20 from the early and 6 from the late stage. The expression profile based on the 20 genes, marked by a preferential decrease in expression level towards invasive phenotype, discriminated the majority of DCIS samples. Thus, this study revealed a gene expression signature with the potential to predict DCIS progression and, consequently, provides opportunities to tailor treatments for DCIS patients.engopenAccessbreast cancerductal carcinoma in situ progressiongene signaturecellular-based analysismolecular markersreceptor expressionsignaling pathwaydown-regulationwilms-tumorprofilespromoteswnterythropoietintransitionmanagementarticleCopyright IMPACT JOURNALS LLC10.18632/oncotarget.12352OncologyCell Biology